TrialDiabetes care2012

Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.

Michaela Diamant et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.